GTBP · Insider Trading
GT Biopharma Inc. Common Stock
Every open-market purchase and sale reported by GTBP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-08 | Charles J Casamento | Director | A | +62,500 deriv. | — |
| 2025-09-08 | David C. Mun-Gavin | Director | A | +31,250 deriv. | — |
| 2025-09-08 | Hilary Kramer | Director | A | +31,250 deriv. | — |
| 2025-09-08 | Michael Martin Breen | CEO and Director | A | +300,000 deriv. | — |
| 2025-09-08 | Alan Louis Urban | Chief Financial Officer | A | +100,000 deriv. | — |
| 2024-10-21 | Alan Louis Urban | Chief Financial Officer | A | +23,335 deriv. | — |
| 2023-08-15 | Michael Martin Breen | Executive Chairman/Interim CEO | A | +200,000 | +$57.40K |
| 2023-08-15 | Manu Ohri | CFO & Secretary | MIXED | +200,000 | +$57.40K |
| 2023-06-21 | Charles J Casamento | Director | A | +500,000 deriv. | — |
| 2023-04-11 | Michael Martin Breen | Executive Chairman/Interim CEO | Buy | +50,000 | +$25.00K |
| 2023-04-10 | Manu Ohri | CFO & Secretary | Buy | +50,000 | +$25.00K |
| 2023-02-01 | Manu Ohri | Chief Financial Officer | A | +500,000 deriv. | — |
| 2023-02-01 | Michael Martin Breen | Exec Chairman and Interim CEO | A | +500,000 deriv. | — |
| 2023-02-01 | Rajesh C Md Shrotriya | Director | A | +500,000 deriv. | — |
| 2023-02-01 | Bruce Wendel | Director | A | +500,000 deriv. | — |
| 2022-07-19 | Alan Louis Urban | Director | A | +50,000 deriv. | — |
| 2022-07-19 | Michael Martin Breen | Exec. Chair. and Interim CEO | A | +278,058 | — |
| 2022-07-19 | Rajesh C Md Shrotriya | Director | A | +461,476 deriv. | — |
| 2022-07-19 | Manu Ohri | CFO & Secretary | MIXED | +100,000 | — |
| 2022-07-19 | Bruce Wendel | Director | A | +100,000 deriv. | — |
| 2022-07-19 | Gregory Berk | Pres. of R&D, CMO | A | +50,000 deriv. | — |
| 2022-02-14 | Rajesh C Md Shrotriya | Director | A | +50,000 deriv. | — |
| 2022-02-14 | Gavin Choy | Acting Chief Financial Officer | A | +227,500 deriv. | — |
| 2022-02-14 | Gregory Berk | Director | A | +278,058 | — |
| 2021-11-12 | Michael Martin Breen | Director | MIXED | +328,160 | +$170.35K |
| 2021-10-07 | Bruce Wendel | Director | MIXED | +352,655 | +$26.30K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael Martin Breen | CEO and Director | 1,142 | $5.79K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GTBP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.